T.gondii p24
Toxoplasma protein is >90% pure as determined by SDS-PAGE.
Description
The E.Coli derived recombinant protein contains the p24 (GRA1) immunodominant regions, fused to six histidines at C-terminal.
Product Specs
This recombinant protein, derived from E. coli, encompasses the immunodominant regions of p24 (GRA1) from Toxoplasma gondii. It is engineered with a six-histidine tag fused at the C-terminus.
The purity of the Toxoplasma protein exceeds 90%, as determined by SDS-PAGE analysis.
The protein is supplied at a concentration of 1 mg/ml in a solution of 1X PBS (pH 7.2) and 50% glycerol.
For short-term storage, Toxoplasma Protein remains stable at 4°C for up to 1 week. For long-term storage, it is recommended to store the protein below -18°C. Repeated freeze-thaw cycles should be avoided to maintain protein integrity.
Product Science Overview
GRA1 is a 23-kDa calcium-binding protein that is secreted by T. gondii into the parasitophorous vacuole, where it plays a crucial role in the parasite’s interaction with the host cell . This protein is highly immunogenic, meaning it can induce strong immune responses in the host. It is recognized by the immune system during both acute and chronic phases of infection, making it a valuable target for diagnostic and vaccine development .
Recombinant GRA1 (p24) refers to the GRA1 protein that has been produced using recombinant DNA technology. This involves cloning the gene encoding GRA1 into a suitable expression system, such as Escherichia coli (E. coli), to produce large quantities of the protein . The recombinant protein is then purified using chromatographic techniques to achieve high purity levels, typically over 90% .
-
Diagnostic Use: Recombinant GRA1 is used as an antigen in enzyme-linked immunosorbent assays (ELISAs) and Western blots for the detection of T. gondii infections. Its high immunogenicity ensures minimal specificity problems, making it an excellent marker for serodiagnosis .
-
Vaccine Development: Due to its ability to induce both humoral and cellular immune responses, GRA1 is considered a promising candidate for vaccine development. Studies have shown that vaccination with GRA1 can provide protective immunity in animal models .
-
Research: Recombinant GRA1 is also used in various research applications to study the biology of T. gondii and its interaction with the host immune system. It helps in understanding the mechanisms of immune evasion and pathogenesis employed by the parasite .
